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Abstract
Background. The independent effects of depressive symptoms and sleep problems for future
physical illness risk have yet to be studied systematically across a variety of disease endpoints.
Methods. We analysed data from 7395 participants (65.81 ± 9.39 years; 54.8% female) from
the English Longitudinal Study of Ageing (ELSA). Baseline was wave 4 and participants
were followed up for 6 years until wave 7. Sleep was measured using an adapted version of
the Jenkins Sleep Problems questionnaire and depressive symptoms using the Centre for
Epidemiological Studies Depression scale. Participants with the illness of interest at baseline
[coronary heart disease (CHD), cancer, diabetes/high blood glucose, arthritis] were excluded
from models predicting the onset of that illness at follow-up. Logistic regression was used,
entering depressive symptoms and sleep problems simultaneously into models controlling
for a wide range of covariates.
Results. In fully adjusted models depressive symptoms predicted incident CHD (OR 1.11,
95% CI 1.04–1.20, p = 0.004) and diabetes/high blood glucose (OR 1.13, 95% CI 1.04–1.22,
p = 0.002) independent of sleep problems; both depressive symptoms (OR 1.10, 95% CI
1.04–1.16, p = 0.002) and sleep problems (OR 1.14, 95% CI 1.02–1.26, p = 0.019) predicted
incident arthritis.
Conclusions. Sleep problems and depressive symptoms, and a combination of both, were
differentially associated with physical illness onset 6 years later. Our findings highlight the
importance of taking into account somatic and affective experiences when looking across a
variety of different physical illnesses.
Introduction
Depression in physical illness is highly prevalent (Moussavi et al., 2007). Several good quality
reviews have also shown that depression can lead to physical illness onset. For example, a
meta-analysis of longitudinal studies showed depressed individuals to be at a 60% greater
risk of developing type II diabetes than those without depression (Mezuk et al., 2008).
Depression has also been implicated in the aetiology of coronary heart disease (CHD)
(Kuper et al., 2002; Rugulies, 2002; Nicholson et al., 2006), stroke (Pan et al., 2011), cancer
(Chida et al., 2008), and dementia (Diniz et al., 2013). However, the precise mechanism of
this effect is unclear. Notably, the somatic dimension of depression symptomatology may
be particularly important in understanding this association (Ormel and de Jonge, 2011;
Poole et al., 2011; Carney and Freedland, 2012).
One somatic symptom of depression that is also known to be independently associated
with the disease is sleep. Several reviews have described the relationship between depression
and sleep (Benca et al., 1992; Tsuno et al., 2005; Benca and Peterson, 2008). Depression is fre-
quently accompanied by changes to sleep, and patients with major depressive disorder (MDD)
are more likely than those without to experience problems with sleep onset, sleep maintenance
and early morning awakenings (Benca and Peterson, 2008); these findings have been con-
firmed using objective readings of sleep collected via actigraphy and polysomnography
(Tsuno et al., 2005). However, despite sleep disturbance being a diagnostic characteristic of
MDD, the relationship between depression and sleep is now considered bidirectional. For
example, depression is highly prevalent in those with insomnia (Taylor et al., 2005) and per-
sons with insomnia are also at increased risk of developing a new-onset depressive episode
compared with those without sleep problems (Riemann and Voderholzer, 2003; Baglioni
et al., 2011). Common biological pathways have been proposed to explain the link between
sleep and depression including changes to sleep architecture, specifically rapid eye movement
(REM) sleep, and neurobiological processes involving deficits in the monoaminergic and
neuroendocrine systems (for a review see Baglioni and Riemann, 2012).
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As alluded to above, poor sleep has been shown to be asso-
ciated with chronic physical illness. A large multi-country study
of over 42 thousand adults aged 50 years and older found elevated
sleep problems in nine different physical illnesses, including
angina, arthritis, diabetes and stroke (Koyanagi et al., 2014).
Sleep duration has been implicated as a risk factor for cancer in
a large prospective cohort study (Gu et al., 2016). However, less
is known about the prospective relationship between sleep,
depression and physical illness, specifically the role of depression
and sleep problems for disease onset. One review that has
attempted to address this issue examined the combined effect of
depressive symptoms and sleep problems for cardiometabolic dis-
ease risk [i.e. cardiovascular disease (CVD) and diabetes] (Mezick
et al., 2011). These authors found evidence for sleep continuity
(i.e. difficulties initiating and maintaining sleep) and depression
being independently associated with CVD, however, findings for
diabetes were inconclusive and further research was recom-
mended. Furthermore, given the high prevalence of comorbidity
in today’s ageing population (Marengoni et al., 2011; Garin
et al., 2016), more research is needed to investigate the role of
depression and sleep for the onset of other chronic illnesses
such as cancer and arthritis.
Several questions remain to be addressed. Firstly, to what
extent do depression and sleep independently predict the onset
of different physical illnesses? Secondly, are there interaction
effects between depression and sleep symptoms such that an addi-
tive effect is more health damaging than either complaint alone?
And thirdly, do similar patterns emerge across different physical
illnesses or are there similar associations across conditions?
Using nationally representative data from the English
Longitudinal Study of Ageing (ELSA) (Steptoe et al., 2013) we
aimed to address these three research questions. This cohort of
adults aged 50 years or older is pertinent to answer these research
questions given the greater prevalence of physical illnesses in
older adults (Manini, 2011). These were exploratory analyses, so
no directional hypotheses were made.
Methods
Sample and study design
Data were taken from ELSA, a nationally representative general
population study of adults aged 50 years and older living in
England. Further details can be found elsewhere (Steptoe et al.,
2013). The sample is followed up every 2 years from 2002
onwards, with refresher samples being added at waves 3, 4 and
6. Wave 7 is the most recently completed phase of data collec-
tion. At every wave, participants complete a computer-assisted
personal interview plus a self-completion questionnaire. On
alternate waves, a nurse visit is conducted to allow for the collec-
tion of blood samples and objective assessments of physical
function, such as body mass index (BMI). Nurse visits were
only conducted on core sample members who had an interview
in person.
This current paper reports data spanning 6 years, from wave 4
(2008/09) through to wave 7 (2014/15), of core members with
nurse visit data. Wave 4 was selected as a baseline since this
was the first point at which sleep data were collected. Complete
case analysis was performed on a sample of 7395 participants
(65.81 ± 9.39 years; 54.8% female) who provided data on inde-
pendent and dependent variables and covariates. A flow diagram
of how the sample was derived is provided in Fig. 1. Overall,
compared with those excluded from these analyses, those
included were more likely to be cohabiting (χ2 = 25.09, p <
0.001), from a higher wealth quintile (χ2 = 101.37, p < 0.001),
have lower adapted (term explained in Section 2.2.1 below)
CES-D scores (t = 6.63, p < 0.001), engage in more regular exercise
(χ2 = 30.59, p < 0.001) and consume alcohol more frequently (χ2 =
88.90, p < 0.001). They were also less likely to have hypertension
(χ2 = 4.43, p = 0.036). Specific Ns are reported for models relating
to each incident illness.
Measures
Depressive symptoms
Depressive symptoms were measured at baseline using the eight-
item Centre for Epidemiological Studies Depression scale
(CES-D). The CES-D measures symptoms that can be used to
identify people at risk of depression, rather than clinical depres-
sion per se (Radloff, 1977). The psychometric properties of the
eight-item version have been shown to be comparable with the
original 20-item version (Steffick, 2000). For the purpose of ana-
lyses described here the sleep item was removed from the CES-D
so as to avoid the issue of shared variance with the sleep problems
measure, hence we term this measure an ‘adapted CES-D’. The
Cronbach’s alpha for the adapted CES-D in this study was 0.80.
We computed a summary score by adding responses to all
seven dichotomous questions (possible range: 0–7).
Sleep problems
Sleep problems were measured with three questions referring to
the most frequent insomnia symptoms, including difficulties fall-
ing asleep, waking up several times a night and waking up in the
morning feeling tired. These sleep items were derived from the
Jenkins Sleep Problems Scale (Jenkins et al., 1988). Participants
answered these questions with regards to the past month. Items
were rated on a 4-point Likert scale ranging from ‘not during
the past month’ to ‘three of more times a week’. Scores were aver-
aged (range 1–4) with higher scores indicating more sleep pro-
blems. The Cronbach’s alpha at wave 4 for this sample was 0.60.
Incident chronic disease
Participants were shown a list of illnesses and asked to self-report
any doctor diagnosed illnesses they had received. The incident
chronic disease was defined as a positive report of CHD, cancer,
diabetes/high blood glucose or arthritis by participants at waves 5,
6 and 7, excluding participants who reported that same chronic
illness at wave 4 baseline. These diseases were selected based on
their consistency of reporting across waves and due to their preva-
lence in ELSA. CHD was defined to include all cases of angina
and myocardial infarction. To avoid self-reporting errors, arthritis
was coded to include osteoarthritis, rheumatoid and arthritis, type
not specified cases. The categorisation of diabetes/high blood
glucose included both participant self-reports of the illness as
well as a positive glycated haemoglobin (HbA1c) value. HbA1c
was assessed from blood drawn from participants’ forearm dur-
ing the nurse visits at waves 4 and 6. Participants who had a clot-
ting or bleeding disorder and those on anti-coagulant
medication did not provide blood samples. Fasting samples,
defined as not eating or drinking for 5 h prior to blood draw,
were collected where possible and when not otherwise contrain-
dicated (e.g. >80 years, diabetic, frail or unwell, ever had a seiz-
ure). All blood samples were analysed at the Royal Victoria
Infirmary laboratory in Newcastle upon Tyne, UK. A detailed
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description of blood analyses is available elsewhere (Sproston
and Mindell, 2004). At wave 6, HbA1c was analysed in the
International Federation of Clinical Chemistry units (mmol/
mol) rather than the Diabetes Control and Complications
Trial (%) units. For consistency wave 6 values were converted
to % using the formula (XX/10.929) + 2.15. We used the classi-
fication of greater than 6.5% HbA1c to signify probable diabetes
as recommended by the World Health Organisation (World
Health Organization, 2011).
Covariates
Covariates were all measured at baseline. Sociodemographic vari-
ables include age, sex, and whether participants were married or
cohabiting with a partner. Socioeconomic status was included in
models as quintiles of net financial wealth, which refers to parti-
cipants’ gross financial wealth with financial debt subtracted.
Height and weight were collected during the wave 4 nurse visit
and BMI was derived using the standard formula (kg/m2).
Whether or not participants reported being a current smoker
(yes/no) and frequency of alcohol consumption (<twice a year/
never, 1–2 times a month/every 2 months, 1–4 times per week,
>5 times per week) were also included in models. Participants
reported the frequency in which they engaged in vigorous, mod-
erate and mild physical activity and we used these data to derive
two possible categories reflecting regularity of physical activity:
moderate/vigorous activity once a week or less, moderate/vigorous
activity more than once a week. Doctor diagnosis of hypertension
or use of anti-hypertensive medication was self-reported and
these responses were combined with objective assessments taken
at the nurse visit (hypertension defined as systolic blood pressure
>140 and diastolic blood pressure >90) to generate a binary vari-
able (yes/no); hypertension was included in models to predict the
cardiometabolic diseases (i.e. CHD and diabetes/high blood
glucose).
Statistical analysis
Associations between variables were assessed using Pearson’s cor-
relations for continuous data and independent t tests for categor-
ical data. Skewness and kurtosis values were within the acceptable
range for all variables, and multicollinearity, assessed by examin-
ing variance inflation factors, was not apparent in any of the stat-
istical models performed. Logistic regression was used to examine
the relationship between baseline continuous adapted CES-D
Fig. 1. Flow diagram of sample.
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scores and sleep problem scores and incident morbidity reported
between waves 5 and 7, controlling for covariates. Logistic regres-
sion was selected for two important reasons. First, creating a time
variable using self-reported month and year of disease onset
resulted in the loss of a large number of cases due to missing
data. Second, creating a time variable based on the year of first
reporting is arbitrary and is of little clinical value given partici-
pants were only assessed biennially. Depressive symptoms and
sleep problems were entered into models simultaneously to assess
the independent contribution of each variable over the other for
predicting incident illness. Covariates were selected based on a
priori knowledge and included age, sex, relationship status,
wealth, smoking, BMI, frequency of alcohol consumption and
regular physical activity. Hypertension was included in models
to predict the cardiometabolic diseases: CHD and diabetes/high
blood glucose. Variables were entered into models in two steps;
first depressive symptoms and sleep were included and next all
the covariates were entered into fully adjusted models. Separate
models were performed to predict incident CHD, diabetes/high
blood glucose, cancer and arthritis.
Secondary analyses were also performed looking at the inter-
action between depressive symptoms and sleep problems for pre-
dicting each incident illness. For these analyses, we created a
binary variable (yes/no) using the standard cut-off on the
CES-D of ⩾4. This represents a conservative estimate given our
use of an adapted 7-item version of this scale and has been
used by others (Steffick, 2000; Hamer et al., 2009; Bell et al.,
2017). Sleep problems were transformed into a binary variable
using a median split. Using these two binary variables, four cat-
egories were created, namely: low depressive symptoms/low
sleep problems, high depressive symptoms/low sleep problems,
low depressive symptoms/high sleep problems, and high depres-
sive symptoms/high sleep problems. This categorical variable
was entered into logistic regression models, using the low depres-
sive symptoms/low sleep problem as the reference category, to
predict incident CHD, diabetes/high blood glucose, cancer and
arthritis, controlling for covariates.
Finally, sensitivity analyses were performed, to assess the effect
of depressive symptoms and sleep symptoms on the incident dis-
ease when events reported within 1 wave of baseline were
excluded from analyses. Results for all these models are presented
as odds ratios (OR) with 95% confidence intervals (CI). All ana-
lyses were conducted using SPSS version 21. Two-tailed tests were
used throughout and the significance level was set at p < 0.05,
though exact significance levels are reported.
Results
Table 1 displays the characteristics of the sample at baseline and
follow-up, with regards to sociodemographic, behavioural,
mood, sleep and incident chronic illness variables. The average
age of the sample was 65.81 (±9.39) years, with a majority of
participants falling within the 60–69 years age bracket.
Approximately half of the participants were female and just
over 70% were married or cohabiting with a partner. There was
a good distribution of participants across each wealth quintile,
from lowest to highest. In terms of the health and health beha-
viours of participants, the majority were non-smokers but did
not engage in regular moderate or vigorous physical activity
more than once a week. Just over half of the sample was hyperten-
sive or on antihypertensive medication. While in general depres-
sive symptom scores were low, 745 (10.1%) of the sample scored
positively for elevated depressive symptoms using the adapted
CES-D cut-off ⩾4. Chronic illnesses were prevalent in the sample
(see Table 1), and in terms of incident illnesses (i.e. excluding
those with the illness at baseline), the most common diagnoses
at follow-up were arthritis followed by cancer and diabetes/high
blood glucose. Depressive symptoms and sleep problem scores
were significantly correlated (r = 0.35, p < 0.001).
Depressive symptoms and sleep predicting incident CHD
In models to predict incident CHD, the sample size was 5034 with
308 incident cases over follow-up. In unadjusted models adapted
CES-D score (OR 1.16, 95% CI 1.09–1.24, p < 0.001) but not sleep
problems (OR 1.11, 95% CI 0.96–1.28, p = 0.147) was a significant
Table 1. Demographic, clinical and biological characteristics of the sample
(N = 7395)
Characteristic Mean ± S.D. or N (%)
Baseline sociodemographics
Age (years) 65.81 ± 9.39
Female 4049 (54.8)
Married/cohabiting 5209 (70.4)
Net financial wealth – quintiles
1 1151 (15.6)
2 1427 (19.3)
3 1489 (20.1)
4 1590 (21.5)
5 1738 (23.5)
Baseline health and health behaviour
Current smoker 977 (13.2)
Moderate/vigorous physical activity ⩾1 a week 2167 (29.3)
Alcohol consumption
>5 times per week 1533 (20.7)
1–4 days per week 2663 (36.0)
1–2 times a month/every 2 months 1281 (17.3)
<Twice a year/never 1918 (25.9)
Body mass index (kg/m2) 28.25 ± 5.29
Hypertension 3954 (53.5)
Baseline mood and sleep problems
CES-D adapted 0.99 ± 1.64
CES-D adapted ⩾4 745 (10.1%)
Sleep problems 2.28 ± 0.89
Follow-up incident morbidity
CHDa 308 (6.1)
Diabetes/high blood glucoseb 304 (8.4)
Cancerc 448 (8.6)
Arthritisd 695 (19.3)
aN = 5034.
bN = 3637.
cN = 5236.
dN = 3611.
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predictor of incident CHD. In final models baseline adapted
CES-D score (OR 1.11, 95% CI 1.04–1.20, p = 0.004) remained
significantly related to an increased odds in CHD after controlling
for covariates (see Table 2). Sleep problems were marginally non-
significant (OR 1.15, 95% CI 1.00–1.34, p = 0.057). These results
suggest for every 1 point increase in depressive symptoms there
was an 11% increase in the odds of experiencing incident CHD.
Secondary fully adjusted analyses to examine the interaction
between depressive symptoms and sleep showed that compared
with those with low depressive symptoms/low sleep problems
(n = 2531) there was an increased odds in future CHD incidence
associated with each depressive symptoms/sleep problems com-
bination. Specifically, compared with the reference group, the
high depressive symptoms/low sleep problems group (n = 82)
(OR 3.73, 95% CI 2.00–6.89, p < 0.001), the low depressive symp-
toms/high sleep problems (n = 2069) (OR 1.36, 95% CI 1.04–1.76,
p = 0.023) and the high depressive symptoms/high sleep problems
group (n = 352) (OR 1.74, 95% CI 1.13–2.68, p = 0.011) were asso-
ciated with an increase in the odds of CHD at 6 year follow-up.
Sensitivity analyses were also performed, removing partici-
pants who developed CHD within 1 wave of baseline. The sample
size for these analyses reduced to 4858 with 132 incident cases of
CHD. The results of the main analysis were attenuated with
depressive symptoms (OR 1.11, 95% CI 1.00–1.24, p = 0.055)
and sleep problems (OR 1.05, 95% CI 0.85–1.30, p = 0.666) asso-
ciated with a non-significant increase in odds of incident CHD.
The interaction analyses were also attenuated in these sensitivity
analyses (results not reported).
Depressive symptoms and sleep predicting incident diabetes/
high blood glucose
In models to predict incident diabetes/high blood glucose, the
sample size was 3637 with 304 incident cases over follow-up. In
unadjusted models, adapted CES-D score (OR 1.22, 95% CI
1.14–1.30, p < 0.001) but not sleep problems (OR 1.02, 95% CI
0.88–1.18, p = 0.787) predicted incident diabetes/high blood glu-
cose. In fully adjusted models depressive symptoms (OR 1.13,
95% CI 1.04–1.22, p = 0.002) remained a significant predictor of
incident diabetes/high blood glucose. Sleep problems were not a
significant predictor in fully adjusted models (OR 0.99, 95% CI
0.85–1.16, p = 0.922). See Table 3 for these results. These results
suggest that for every 1 point increase in depressive symptoms
there was a 13% increase in the odds of experiencing incident dia-
betes/high blood glucose. Secondary analyses revealed no signifi-
cant interaction effects between depressive symptoms and sleep
problems (results not reported).
Table 2. Baseline depressive symptoms predicting incident CHD at follow-up
(N = 5034)
OR 95% CI P
Baseline depressive symptoms 1.11 1.04–1.20 0.004
Baseline sleep problems 1.15 1.00–1.34 0.057
Age (years) 1.07 1.05–1.08 <0.001
Sexa 0.50 0.39–0.65 <0.001
Relationship statusb 0.68 0.51–0.91 0.009
Wealth
1 Reference
2 0.71 0.49–1.03 0.069
3 0.544 0.37–0.81 0.002
4 0.584 0.39–0.86 0.007
5 0.504 0.33–0.76 0.001
BMI (kg/m2) 1.02 1.00–1.04 0.090
Smokerc 0.66 0.46–0.94 0.023
Alcohol consumption
>5 times per week Reference
1–4 days per week 1.00 0.71–1.40 0.977
1–2 times a month/every 2
months
1.01 0.67–1.53 0.952
<Twice a year/never 1.44 1.01–2.07 0.046
Physical activityd 0.71 0.52–0.96 0.026
Hypertensione 1.63 1.25–2.12 <0.001
aFemale.
bMarried/cohabiting.
cSmoker.
dModerate/vigorous physical activity <1 a week.
eNot hypertensive.
N.B. Data represent the fully adjusted model.
Table 3. Baseline depressive symptoms predicting incident diabetes/high blood
glucose at follow-up (N = 3637)
OR 95% CI P
Baseline depressive symptoms 1.13 1.04–1.22 0.002
Baseline sleep problems 0.99 0.85–1.16 0.922
Age (years) 1.03 1.02–1.05 <0.001
Sexa 0.55 0.42–0.72 <0.001
Relationship statusb 0.90 0.66–1.21 0.474
Wealth
1 Reference
2 0.79 0.54–1.17 0.240
3 0.67 0.45–1.01 0.054
4 0.53 0.34–0.81 0.004
5 0.60 0.39–0.92 0.020
BMI (kg/m2) 1.15 1.12–1.17 <0.001
Smokerc 0.54 0.38–0.77 0.001
Alcohol consumption
>5 times per week Reference
1–4 days per week 1.08 0.75–1.56 0.672
1–2 times a month/every 2
months
1.61 1.07–2.42 0.023
<Twice a year/never 1.23 0.82–1.83 0.317
Physical activityd 0.57 0.42–0.79 0.001
Hypertensione 1.88 1.43–2.46 <0.001
aFemale.
bMarried/cohabiting.
cSmoker.
dModerate/vigorous physical activity <1 a week.
eNot hypertensive.
N.B. Data represent the fully adjusted model.
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Sensitivity analyses were also performed, removing partici-
pants who developed diabetes/high blood glucose within 1 wave
of baseline. The sample size for these analyses reduced to 3551
with 218 incident cases of diabetes/high blood glucose. The
results of the main analysis were replicated with depressive symp-
toms (OR 1.10, 95% CI 1.01–1.21, p = 0.037) but not sleep pro-
blems (OR 0.96, 95% CI 0.80–1.16, p = 0.691) associated with a
significant increase in odds of incident diabetes/high blood
glucose.
Depressive symptoms and sleep predicting incident cancer
In models to predict incident cancer, the sample size was 5236
with 448 incident cases over follow-up. In unadjusted models,
neither adapted CES-D score (OR 1.06, 95% CI 0.99–1.12, p =
0.088) nor sleep problems (OR 1.09, 95% CI 0.97–1.22, p =
0.159) predicted incident cancer 6 years later. Similarly, in final
models neither depressive symptoms (OR 1.05, 95% CI 0.98–
1.12, p = 0.137) nor sleep problems (OR 1.11, 95% CI 0.98–1.25,
p = 0.096) were a significant predictor of incident cancer, inde-
pendent of covariates.
However, secondary fully adjusted analyses to examine the
interaction between depressive symptoms and sleep showed that
compared with those with low depressive symptoms/low sleep
problems (n = 2584) those with high depressive symptoms/high
sleep problems group (n = 373) were at increased odds of incident
cancer (OR 1.67, 95% CI 1.17–2.39, p = 0.004) suggesting a com-
bined deleterious effect for future cancer risk with a 67% increase
in odds for this group compared with those low in depressive
symptoms and sleep problems. Compared with the reference
group, neither the high depressive symptoms/low sleep problems
(n = 87) (OR 0.79, 95% CI 0.34–1.85, p = 0.584) nor the low
depressive symptoms/high sleep problems (n = 2192) (OR 1.06,
95% CI 0.86–1.31, p = 0.597) group were at increased odds of inci-
dent cancer at follow-up (see Table 4).
Sensitivity analyses were also performed, removing partici-
pants who developed cancer within 1 wave of baseline. The sam-
ple size for these analyses reduced to 5054 with 266 incident cases
of cancer. Analyses looking at the interaction between depressive
symptoms and sleep problems were confirmed in these sensitivity
analyses, with only those with high depressive symptoms/high
sleep problems group (n = 358) at increased odds of incident
cancer (OR 1.86, 95% CI 1.21–2.85, p = 0.005) compared with
the low depressive symptoms/low sleep problems reference
group (n = 2501).
Depressive symptoms and sleep predicting incident arthritis
In models to predict incident arthritis, the sample size was 3611
with 695 incident cases over follow-up. In unadjusted models,
adapted CES-D score (OR 1.12, 95% CI 1.06–1.18, p < 0.001)
and sleep problems (OR 1.19, 95% CI 1.08–1.32, p = 0.001)
were both independent predictors of incident arthritis. In final
models, baseline adapted CES-D score (OR 1.10, 95% CI 1.04–
1.16, p = 0.002) and sleep problems (OR 1.14, 95% CI 1.02–
1.26, p = 0.019) remained significant (see Table 5). These results
suggest that for every 1-point increase in depressive symptoms
there was a 10% increase in the odds and with every 1-point
increase in sleep problems there was a 14% increase in the odds
of incident arthritis.
Secondary fully adjusted analyses to examine the interaction
between depressive symptoms and sleep showed that compared
with those with low depressive symptoms/low sleep problems
(n = 1983) those with low depressive symptoms/high sleep pro-
blems (n = 1387) (OR 1.32, 95% CI 1.11–1.58, p = 0.002) were
at increased odds of incident arthritis. There was also a significant
detrimental effect for the high depressive symptoms/high sleep
problems group (n = 186) (OR 1.86, 95% CI 1.30–2.64, p =
0.001) compared with those low in these symptoms. However,
compared with the reference group, the high depressive symp-
toms/low sleep problems group (n = 55) (OR 1.77, 95% CI
0.97–3.27, p = 0.065) were not at increased odds of incident
arthritis.
Sensitivity analyses were also performed, removing partici-
pants who developed arthritis within 1 wave of baseline. The sam-
ple size for these analyses reduced to 3326 with 410 incident cases
of arthritis. Results from the main analysis corroborated the sig-
nificant relationship between sleep problems (OR 1.18, 95% CI
1.03–1.35, p = 0.014) and future arthritis. However, depressive
symptoms (OR 1.07, 95% CI 1.00–1.16, p = 0.056) were
Table 4. Elevated depressive symptoms and elevated sleep problems predicting
incident cancer at follow-up (N = 5236)
OR 95% CI p
adapted CES-D × sleep interaction
Low depressive symptoms/low
sleep problems
Reference
High depressive symptoms/low
sleep problems
0.79 0.34–1.85 0.584
Low depressive symptoms/high
sleep problems
1.06 0.86–1.31 0.597
High depressive symptoms/high
sleep problems
1.67 1.17–2.39 0.004
Age (years) 1.04 1.03–1.05 <0.001
Sexa 0.89 0.72–1.09 0.246
Relationship statusb 0.94 0.74–1.19 0.585
Wealth
1 Reference
2 1.02 0.71–1.45 0.930
3 1.19 0.84–1.70 0.321
4 1.21 0.85–1.72 0.290
5 1.08 0.75–1.55 0.698
BMI (kg/m2) 1.01 0.99–1.03 0.289
Smokerc 0.82 0.60–1.11 0.201
Alcohol consumption
>5 times per week Reference
1–4 days per week 0.97 0.75–1.26 0.819
1–2 times a month/every 2
months
0.83 0.59–1.15 0.250
<Twice a year/never 0.87 0.64–1.178 0.362
Physical activityd 0.79 0.62–0.99 0.040
aFemale.
bMarried/cohabiting.
cSmoker.
dModerate/vigorous physical activity <1 a week.
N.B. Data represent the fully adjusted model.
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marginally non-significant. Sensitivity analyses looking at the
interaction between depressive symptoms and sleep problems
showed the same pattern of findings as was found in the main
analyses, with those with low depressive symptoms/high sleep
problems (n = 1266) (OR 1.37, 95% CI 1.10–1.71, p = 0.006) and
those with high depressive symptoms/high sleep problems (n =
163) (OR 1.94, 95% CI 1.26–3.00, p = 0.003) being associated
with an increased odds of future arthritis compared with the
low depressive symptoms/low sleep problems reference group
(n = 1850).
Discussion
This study sought to examine the combined effect of depressive
symptoms and sleep problems for incident physical illness onset
up to 6 years later in a nationally representative cohort of adults
aged 50 years and older. The principle findings showed that
depressive symptoms predicted incident CHD and diabetes/high
blood glucose independent of sleep problems. Both depressive
symptoms and sleep problems predicted incident arthritis even
after taking into consideration a wide range of sociodemographic,
behavioural and clinical factors. No main effects were evident for
predicting cancer, however, a combination of elevated sleep pro-
blems and elevated depressive symptoms was associated with
increased odds. Results for diabetes/high blood glucose and can-
cer, but not CHD, were replicated in sensitivity analyses excluding
participants who reported disease within 1 wave of baseline.
Findings for arthritis were partly replicated in sensitivity analyses
though depressive symptoms were no longer significant in the
main effects model. These null findings for CHD and arthritis
in our sensitivity analyses could possibly indicate confounding
by cases diagnosed shortly after baseline or else they could have
been caused by a reduction in the sample size affecting the ability
to detect an effect (e.g. cases reduced from 308 to 132 in the CHD
analyses).
Our main finding was that depressive symptoms and sleep
problems were significantly associated with disease onset in
ELSA, but that the pattern of results varied according to the phys-
ical illness in question. The link between depression and sleep
problems is now well-established (Benca and Peterson, 2008)
though the pathways linking them are not unidirectional
(Staner, 2010). While disturbed sleep is one of the key diagnostic
features of MDD, sleep disturbance is also known to precede the
onset of depression (Roberts et al., 2000; Almeida et al., 2011;
Baglioni et al., 2011). We, therefore, entered depressive symptoms
and sleep scores simultaneously into our models in order to look
at the independent effect of each factor while holding the other
constant. In fully adjusted models depressive symptoms but not
sleep problems predicted the cardiometabolic disorders, namely
CHD and diabetes/high blood glucose, however, both depressive
symptoms and sleep problems were significant predictors after
taking into account multiple confounders in models to predict
arthritis. A combination of elevated sleep problems and elevated
depressive symptoms was a significant predictor of incident can-
cer in fully adjusted models. The interaction between depressive
symptoms and sleep problems was also apparent for CHD and
arthritis. These results add credence to research supporting the
independent effect of depressive symptoms and sleep problems
for health outcomes.
Many studies have looked at the role of depression for disease
risk, for example, depression has been shown to predict the onset
of CHD (Kuper et al., 2002; Rugulies, 2002; Nicholson et al.,
2006), diabetes (Mezuk et al., 2008) and cancer (Chida et al.,
2008). Indeed, previously published work using ELSA has sup-
ported the link between depression and risk of diabetes
(Demakakos et al., 2010). The magnitude of the effect of depres-
sive symptoms was similar in our models to predict both CHD
and diabetes/high blood glucose, with an 11% and 13% increase
in the odds of disease onset respectively, for every 1-point increase
in the adapted CES-D score. In arthritis models, a 1-point
increase in sleep problems was associated with a larger increase
in odds compared with a 1-point increase in depressive symptoms
(14% v. 10%). Direct comparisons with previous studies are cir-
cumvented by differences in measurement and analysis. For
example, Nicholson and colleagues (Nicholson et al., 2006)
found depression was associated with a relative risk of CHD of
1.90 (95% CI = 1.49–2.42) in adjusted studies; Mezuk and collea-
gues (Mezuk et al., 2008) found that depression was associated
with a relative risk of diabetes of 1.60 (95% CI = 1.37–1.88).
The evidence of depressive symptoms for arthritis onset is lacking,
though it is thought to confer increased risk (Patten et al., 2008).
For example, one study found that the incidence of rheumatoid
arthritis was higher in depressed than non-depressed individuals
(adjusted hazard ratio = 1.65, 95% CI 1.41–1.77) (Lu et al., 2016).
However, these studies have not taken into account the role of
sleep problems. Sleep problems have been cross-sectionally asso-
ciated with many physical illnesses (Foley et al., 2004; Koyanagi
et al., 2014), but few studies have looked at their relationship
Table 5. Baseline depressive symptoms and sleep problems predicting incident
arthritis at follow-up (N = 3611)
OR 95% CI p
Baseline depressive symptoms 1.10 1.04–1.16 0.002
Baseline sleep problems 1.14 1.02–1.26 0.019
Age (years) 1.02 1.01–1.03 <0.001
Sexa 1.50 1.26–1.79 <0.001
Relationship statusb 1.12 0.91–1.37 0.285
Wealth
1 Reference
2 0.75 0.55–1.02 0.063
3 0.67 0.50–0.91 0.011
4 0.66 0.48–0.89 0.007
5 0.62 0.45–0.84 0.002
BMI (kg/m2) 1.05 1.04–1.07 <0.001
Smokerc 1.25 0.94–1.66 0.125
Alcohol consumption
>5 times per week Reference
1–4 days per week 1.07 0.85–1.35 0.584
1–2 times a month/every 2
months
0.91 0.68–1.21 0.495
<Twice a year/never 1.00 0.76–1.31 0.989
Physical activityd 1.07 0.89–1.29 0.477
aFemale.
bMarried/cohabiting.
cSmoker.
dModerate/vigorous physical activity <1 a week.
N.B. Data represent the fully adjusted model.
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with disease onset using prospective analyses. There is some evi-
dence sleep problems play a role in CHD mortality in males
(Mallon et al., 2002) and as a risk factor for incident MI
(Schwartz et al., 1998). There is also some evidence to suggest
that sleep problems (specifically difficulties initiating and main-
taining sleep) are predictive of incident diabetes in men
(Mallon et al., 2005). Sleep problems have not been investigated
with regards to cancer onset, though there is some evidence for
the role of sleep duration (Gu et al., 2016).
The combined effect of sleep problems and depressive symp-
toms has been little studied in relation to disease onset, and
work has tended to focus on cardiometabolic diseases (Mezick
et al., 2011). To the best of our knowledge, our study is the first
to systematically investigate the longitudinal effect of sleep pro-
blems and depressive symptoms for disease onset, across a variety
of disease types. Our interaction analyses partly support the con-
clusions of Mezick et al. (2011) who suggest sleep problems to be
a risk factor for CVD, independent of depression, but that incon-
clusive evidence exists for metabolic diseases (i.e. diabetes). We
have added to this body of work showing that sleep problems
may also play a role in the onset of arthritis. Further work is
needed to corroborate the null findings for diabetes/high blood
glucose that we report here for sleep, perhaps using a longer
length of follow-up and further distinguishing between insulin
resistance and diabetes.
We also examined interaction effects between depressive
symptoms and sleep problems, to investigate whether there was
any increased risk involved in having one complaint rather than
the other, or whether having both was particularly detrimental
to health. We found that the interaction between depressive
symptoms and sleep was important in predicting incident CHD,
cancer and arthritis. Specifically, high depressive symptoms/low
sleep problems, low depressive symptoms/high sleep problems
and high depressive symptoms/high sleep problems were all pre-
dictive of incident CHD, suggesting a role for both symptom pro-
files in cardiac disease. In models predicting incident cancer, only
the combination of high depressive symptoms/high sleep pro-
blems was a significant predictor, indicating that having eleva-
tions in both symptom profiles was particularly health
damaging. Finally, low depressive symptoms/high sleep problems
and high depressive symptoms/high sleep problems were found to
significantly predict arthritis onset. Overall, these results highlight
the importance of considering the overlap that depression has
with somatic complaints, such as sleep disturbance, as well as
considering them as separate constructs.
One possible way to reconcile the two constructs is to turn to
the literature on vital exhaustion. Vital exhaustion is commonly
defined as symptoms of excessive tiredness, increased irritability
and a sense of demoralisation (Appels et al., 1987). Vital exhaus-
tion has been shown to be predictive of heart disease onset
(Prescott et al., 2003), but there is less evidence for its role in can-
cer (Bergelt et al., 2005). Although depression and vital exhaus-
tion are generally understood to be separate constructs (Kopp
et al., 1998), in a recent study this was only observed in men
and not women (Lindeberg et al., 2012). Another study used prin-
cipal component analyses on questionnaire responses of 528 MI
patients on the Beck Depression Inventory (BDI) and
Maastricht Questionnaire (a measure of vital exhaustion)
(Vroege et al., 2012). These authors showed strong conceptual
overlap between the two scales, with all but two items from the
Maastricht Questionnaire loading on the somatic/affective dimen-
sion of the BDI. Moreover, this somatic/affective dimension was
able to predict recurrent events, but the cognitive/affective dimen-
sion was not. Due to these disparate findings, more research is
needed to delineate the independent effect of vital exhaustion
over and above the constructs of depression and sleep disturb-
ance, on physical disease risk.
There are several possible mechanisms for the link between
sleep and disease onset. Interestingly these pathways are similar
to those proposed to link depression to physical illness (Brown
et al., 2004; Dantzer et al., 2008). Primary biological systems
thought to be implicated include the role the neuroendocrine sys-
tem and in particular, cortisol (Meerlo et al., 2008). Changes to
the neuroendocrine system have been observed after sleep loss,
although the findings are inconsistent, with some studies report-
ing a slight elevation in cortisol in response to sleep deprivation
(Spiegel et al., 1999; Chapotot et al., 2001), while others have
reported no changes or even small decrements in cortisol levels
(Akerstedt et al., 1980; Follenius et al., 1992). Depression has
long been associated with increases in cortisol output (Zunszain
et al., 2011). Modulation of cortisol responses may be particularly
relevant to inflammatory diseases such as CHD and arthritis since
cortisol is known to be involved in regulation of the immune sys-
tem (Maier and Watkins, 1998). Both disturbed and curtailed
sleep have indeed been shown to increase low-grade inflammation
directly (Irwin, 2015) and depression is known to be associated
with pro-inflammatory cytokines such as interleukin-6 (Howren
et al., 2009). Recent evidence suggests that the relationship
between depression and inflammation is symptom-specific, with
the fatigue-type symptoms being most strongly associated with
C-reactive protein, but this effect was absent in those using anti-
depressant medication (White et al., 2017). While such studies
allude to the anti-inflammatory effects of antidepressant medica-
tion, we were unable to take this into account in our analyses since
this information was only collected on a small number of partici-
pants who reported a positive doctor diagnosis of depression in
ELSA. Sleep is known to change with age (Ohayon et al., 2004),
therefore, it is also plausible that sleep effects processes involved
in the biology of ageing such as telomere length (Jackowska
et al., 2012; Tempaku et al., 2015). More work is needed to
tease out the exact pathways by which sleep and depression oper-
ate to affect future disease onset. Our findings suggest sleep pro-
blems and depressive symptoms precede the onset of physical
illness, though causality cannot be ascertained from our work
since sub-clinical measures of disease were not recorded in
ELSA. We attempted to control for this effect in sensitivity ana-
lyses, though longer-term studies are needed to corroborate our
findings.
Our work had a number of strengths. First, our use of nation-
ally representative data, providing us with a large cohort on which
to test our research questions, improves the generalisability of our
findings. We controlled for a wide range of confounders that
might otherwise predict physical illness onset and were still able
to demonstrate an effect. Moreover, the prospective nature of
ELSA allowed us to conduct longitudinal analyses, looking at
the effect of baseline depressive symptoms and sleep problems
for future disease risk. Importantly, looking at multiple disease
outcomes increases the salience of our findings, showing these
factors are likely to be important across a variety of illnesses.
However, a number of weaknesses must also be noted. First,
was our reliance on self-report data of physical illness which
may be prone to recall bias and reporting errors. We tried to cir-
cumvent this limitation by using objective data where possible (i.e.
blood pressure readings and HbA1c values). Second, due to
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missing data regarding the date of illness onset, we were unable to
use survival analysis techniques. Therefore, our study is limited to
observing cases of incident disease and cannot make any claims
about the rate of onset. Third, we investigated the role of depres-
sive symptoms and not MDD, therefore our results are not readily
generalisable to those with clinical episodes of depression. Fourth,
compared with those excluded from analyses, those included
represented a more affluent and healthier subset of individuals,
which may have lead us to underestimate some of the effects.
However, we believe this to be congruent with the fact we have
restricted our sample to those free from physical illness at base-
line. Finally, we were unable to take into account objective mea-
sures of sleep, use of sleep medication, or clinical diagnoses
such as sleep apnoea, since these were not collected in ELSA.
However, our findings do suggest an effect of self-reported sleep
on future disease risk, highlighting the importance of the subject-
ive experience of sleep for future wellbeing.
In conclusion, we found that depressive symptoms predicted
incident CHD and diabetes/high blood glucose, depressive symp-
toms and sleep problems predicted incident arthritis and a com-
bination of elevated depressive symptoms and elevated sleep
problems predicted incident cancer relative to those low in
these symptoms 6 years later in a nationally representative cohort
of adults aged 50 years and older. While mechanisms of the effect
are unclear, our findings point to the importance of simultan-
eously taking into account somatic and affective experiences
when looking across a variety of different physical illnesses.
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